Dubai UAE – December 5, 2025 – Kings Research has released its latest publication titled “Global Biosensors Market Size, Share, Trends, and Forecast 2025-2032”. The report provides an in-depth overview of the biosensors industry, including segmentation by type, technology, application, and region. It offers valuable insights for healthcare providers, medical device manufacturers, biotechnology firms, and investors evaluating growth opportunities in the evolving biosensors market.
According to Kings Research, the global biosensors market was valued at USD 30.23 billion in 2024. It is projected to grow to USD 32.70 billion in 2025 and further expand to USD 61.32 billion by 2032, registering a compound annual growth rate (CAGR) of 9.40% over the forecast period.
This growth is being driven by rising demand for rapid diagnostics, increasing adoption of wearable health monitoring devices, and advances in electrochemical and optical biosensor technologies that enhance accuracy, portability, and real-time data analysis. The incorporation of 2D materials into sensor fabrication is also boosting sensitivity and performance across next-generation biosensing platforms.
The World Health Organization reports that 14% of adults worldwide were living with diabetes in 2022, from 7% in 1990, highlighting a growing global need for continuous and home-based glucose monitoring solutions. Country-level diabetes prevalence data across world regions reinforces this trend, as documented in the WHO Global Health Observatory.
Biosensors are analytical devices that detect and quantify biological or chemical substances by converting biological interactions into measurable electrical, optical, thermal, or mechanical signals. They play a critical role in improving diagnostic accuracy, environmental safety, and process efficiency across healthcare, food and beverage, biotechnology, and environmental monitoring applications.
Regulators are also supporting the adoption of digital biomonitoring technologies, notably, the U.S. Food and Drug Administration’s Digital Health Center of Excellence provides regulatory guidance for medical devices incorporating wearable and sensor-based patient monitoring technologies, enabling safe clinical deployment in both hospital and remote care settings (source: fda.gov). Growing use of biosensors within durable medical equipment further reinforces adoption in long-term patient care and rehabilitation settings.
Key Trends Reshaping the Biosensors Market:
- Expansion of Wearable Health Technologies
Wearable biosensors allow real-time monitoring of physiological parameters such as glucose, heart rate, and oxygen saturation. Integration of biosensors into wearable devices enhances personalized healthcare, supports continuous monitoring, and enables timely medical interventions. For chronic conditions like diabetes, continuous glucose monitoring via biosensors is increasingly critical as rising global diabetes prevalence estimated at 10.5% of adults worldwide as of 2025 by International Diabetes Federation (IDF)(source: idf.org). This creates strong demand for non-invasive, at-home monitoring solutions aligned with innovations in smart home healthcare. - Advances in Electrochemical and Optical Sensor Technologies
The electrochemical segment captured the largest market share of around 71.7% in 2024 and is expected to grow at the fastest CAGR of 8.7% from 2025 to 2030. Improvements in optical sensor platforms also provide rapid and accurate detection capabilities, enabling faster clinical and environmental decision-making. - Strategic Partnerships and R&D Investments
Major players such as Abbott, Medtronic, Roche, DuPont, Bio-Rad, Dexcom, Masimo, and Thermo Fisher are investing in R&D for next-generation biosensor platforms, functionalized and miniaturized devices, and integration with semiconductor technologies. These initiatives enhance device accessibility and accelerate deployment in clinical and home healthcare settings. - Growing Need for Rapid Diagnostics
The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer is driving demand for accurate, point-of-care diagnostic solutions. Real-time monitoring via biosensors allows early detection and improved disease management, reducing complications and healthcare costs. Recent academic work on on-skin biosensing validates this shift. (source: pmc.ncbi.nlm.nih.gov)
Regional Outlook:
- North America: Expected to lead the market due to high adoption of wearable health devices and strong investments in diagnostics.
- Asia-Pacific: Anticipated to grow at the fastest rate (CAGR 10.63%) driven by rising healthcare infrastructure investments, digital health initiatives, and growing chronic disease prevalence.
Competitive Landscape:
Key market participants focus on product innovation, cost-effective manufacturing, and integration with digital healthcare platforms. Leading companies include Abbott, F. Hoffmann-La Roche Ltd, Medtronic, Bio-Rad Laboratories, DuPont, Biosensors International Group, Dexcom, Masimo, Nova Biomedical, Universal Biosensors, Thermo Fisher Scientific, Siemens Healthineers, Johnson & Johnson, Agilent Technologies, and Honeywell International.
These companies are developing next-generation biosensors, forming strategic partnerships, and refining commercialization strategies to improve device accessibility, enable rapid adoption in clinical and home healthcare, and capture wider market share.
To request a sample or access the full Global Biosensors Market Size, Share, Trends, and Forecast 2025-2032 report, visit: https://www.kingsresearch.com/report/biosensors-market-2992
About Kings Research
Kings Research is a global research and consulting firm that helps organizations navigate emerging markets, evaluate investment potential, and make evidence-based strategic decisions.
All market data are sourced from Kings Research proprietary analysis, validated against credible government publications and peer-reviewed research papers. Examples cited include: World Health Organization (WHO), World Health Organization – Global Health Observatory (WHO-GHO), U.S. Food and Drug Administration (FDA), International Diabetes Federation (IDF) and PubMed Central (PMC) – U.S. National Institutes of Health (NIH).